Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: Scope of the problem

Therapeutic Advances in Drug Safety

Volumn 6, Issue 2, 2015, Pages 57-66

  Daley, Mitchell J ^a   Murthy, Manasa S ^b   Peterson, Evan J ^b  

^a University Medical Center Brackenridge   (United States)

^b Seton Medical Center Austin   (United States)

Author keywords

alteplase; bleeding hemorrhage; pulmonary embolism; thrombolytic therapy

Indexed keywords

ALTEPLASE; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RETEPLASE; STREPTOKINASE; TENECTEPLASE; UROKINASE;

BLEEDING; BRAIN HEMORRHAGE; CONTINUOUS INFUSION; DRUG CONTRAINDICATION; FIBRINOLYTIC THERAPY; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; REPERFUSION; REVIEW; RISK FACTOR;

EID: 84926507099     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098615572333     Document Type: Review

References (55)

1. Agnelli G. Becattini C. (2010) Acute pulmonary embolism. N Engl J Med 363: 266–274.
2. Antman E. Morrow D. McCabe C. Murphy S. Ruda M. Sadowski Z. (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354: 1477–1488.
3. Becattini C. Agnelli G. Salvi A. Grifoni S. Pancaldi L. Enea I. (2010) Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 125: e82–e86.
4. Berkowitz S. Granger C. Pieper K. Lee K. Gore J. Simoons M. (1997) Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. Circulation 95: 2508–2516.
5. Bottiger B. Arntz H. Chamberlain D. Bluhmki E. Belmans A. Danays T. (2008) Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med 359: 2651–2662.
6. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group (2003) British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 58: 470–483.
7. Budaj-Fidecka A. Kurzyna M. Fijalkowska A. Zlkowska J. Wieteska M. Florczyk M. (2013) In-hospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of the ZATPOL Registry data. Int J Cardiol 168: 3543–3549.
8. Capstick T. Henry M. (2005) Efficacy of thrombolytic agents in the treatment of pulmonary embolism. Eur Respir J 26: 864–874.
9. Chatterjee S. Chakraborty A. Weinberg I. Kadakia M. Wilensky R. Sardar P. (2014) Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 311: 2414–2421.
10. Curtis G. Lam S. Reddy A. Bauer S. (2014) Risk factors associated with bleeding after alteplase administration for pulmonary embolism: a case-control study. Pharmacotherapy 34: 818–825.
11. Daley M. Lat I. (2012) Clinical controversies in thrombolytic therapy for management of acute pulmonary embolism. Pharmacotherapy 32: 158–172.
12. Dalla-Volta S. Palla A. Santolicandro A. Giuntini C. Pengo V. Visioli O. (1992) PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol 20: 520–526.
13. DuPont-Thibodeau G. Harrington K. Lacroix J. (2014) Anemia and red blood cell transfusion in critically ill cardiac patients. Ann Intensive Care 4: 16.
14. Engelberger R.P. Kucher N., (2011) Catheter-based reperfusion treatment of pulmonary embolism. Circulation. 124: 2139–2144.
15. Fasullo S. Scalzo S. Maringhini G. Ganci F. Cannizzaro S. Basile I. (2011) Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci 341: 33–39.
16. Genentech (2005) Activase (alteplase) package insert. San Francisco, CA: Genentech.
17. Giraldez R. Nicolau J. Corbalan R. Gurfinkel E. Juarez U. Lopez-Sendon J. (2007) Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. Eur Heart J 28: 1566–1573.
18. Go A. Mozaffarian D. Roger V. Benjamin E. Berry J. Borden W. (2013) Heart disease and stroke statistics ∑ 2013 update: a report from the American Heart Association. Circulation 127: e6–e245.
19. Goldhaber S. (2006) Acute pulmonary embolism. Circulation 114: 42–47.
20. Goldhaber S. Agnelli G. Levine M. (1994) Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial. Chest 106: 718–724.
21. Goldhaber S. Haire W. Feldstein M. Miller M. Toltzis R. Smith J. (1993) Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 341: 507–511.
22. Goldhaber S. Kessler C. Heit J. Elliott C. Friedenberg W. Heiselman D. (1992) Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomised controlled multicenter trial. J Am Coll Cardiol 20: 24–30.
23. Goldhaber S. Visani L. De Rosa M. (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353: 1386–1389.
24. GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673–682.
25. Haire W. (1992) Pharmacology of fibrinolysis. Chest 101: 91S–97S.
26. Heit J. Silverstein M. Mohr D. Petterson T. O–Fallon W. Melton L. (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159: 445–453.
27. Jaff M. McMurtry S. Archer S. Cushman M. Goldenberg N. Goldhaber S. (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123: 1788–1830.
28. Kasper W. Konstantinides S. Geibel A. Olschewski M. Heinrich F. Grosser K. (1999) Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 30: 1165–1171.
29. Kearon C. Akl E. Comerota A. Prandoni P. Bounameaux H. Goldhaber S. (2012) Antithrombotic therapy for venous thromboembolism disease. Chest 141: e419–e494.
30. Kline J. Nordenholz K. Courtney D. Kabrhel C. Jones A. Rondina M. (2014) Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost 12: 459–468.
31. Konstantanides S. Geibel A. Heusel G. Heinrich F. Kasper W. (2002) Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347: 1143–1150.
32. Konstantinides S. Torbicki A. Agnelli G. Danchin N. Fitzmaurice D. Galie N. (2014) European Society of Cardiology Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J, DOI: 10.1093/eurheartj/ehu283.
33. Kucher N. Boekstegers P. Mueller O. Kupatt C. Beyer-Westendorf J. Heitzer T. (2014) Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 129: 479–486.
34. Kuo W. Gould M. Louie J. Rosenberg J. Sze D. Hofmann L. (2009) Catheter-directed therapy for treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 20: 1431–1440.
35. Levine M. Hirsh J. Weitz J. (1990) A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 98: 1473–1479.
36. Meneveau N. Schiele F. Metz D. Valette B. Attali P. Vuillemenot A. (1998) Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 31: 1057–1063.
37. Meneveau N. Schiele F. Vuillemenot A. Valette B. Grollier G. Bernard Y. (1997) Streptokinase vs alteplase in massive pulmonary embolism: a randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J 18: 1141–1148.
38. Meyer G. Gisselbrecht M. Diehl J. Journois D. Sors H. (1998) Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 105: 472–477.
39. Meyer G. Sors H. Charbonnier B. Kasper W. Bassand J. Kerr I. (1992) Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol 19: 239–245.
40. Meyer G. Vicaut E. Danays T. Agnelli G. Becattini C. (2014) Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Eng J Med 370: 1402–1411.
41. Muhl D. Furedi R. Gecse K. Ghosh S. Falusi B. Bogar L. (2007) Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism. Blood Coagul Fibrinolysis 18: 661–667.
42. Patra S. Agrawal N. Manjunath N. Nagesh C. Srinivas B. Ravindranath K. (2014) Thrombolytic therapy in the treatment of acute sub-massive pulmonary embolism: a prospective observational trial. Blood Coagul Fibrinolysis 25: 167–171.
43. Patra S. Nagesh C. Reddy B. Srinivas B. Agrawal N. Manjunath C. (2013) Thrombolysis with single bolus tenecteplase compared with streptokinase infusion in the treatment of acute pulmonary embolism: a pilot study. Clin Appl Thromb Hemost, Available at: http://www.ncbi.nlm.nih.gov/pubmed/24254898 (accessed 23 March 2015)
44. Piazza G. (2013) Submassive pulmonary embolism. JAMA 309: 171–180.
45. Piazza G. Goldhaber S. (2006) Acute pulmonary embolism: part II: treatment and prophylaxis. Circulation 114: e42–e47.
46. PIOPED Investigators (1990) Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest 97: 528–533.
47. Sharifi M. Bay C. Skrocki L. Rahimi F. Mehdipoor M. (2013) Moderate pulmonary embolism treated with thrombolysis (from the “MOPPETT” trial). Am J Cardiol 111: 273–277.
48. Sors H. Pacouret G. Azarian R. Meyer G. Charbonnier B. Simonneau G. (1994) Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial. Chest 106: 712–717.
49. Stein P. Matta F. (2010) Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism. Clin Chest Med 31: 611–628.
50. Tapson V. (2008) Acute pulmonary embolism. N Engl J Med 358: 1037–1052.
51. Tebbe U. Graf A. Kamke W. Zahn R. Forycki F. Kratzsch G. (1999) Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 138: 39–44.
52. Tsai J. Crosse S. Grant A. Hooper W. Atrash H. (2012) Trends in in-hospital deaths among hospitalizations with pulmonary embolism. Arch Intern Med 172: 960–961.
53. UPET (1970) Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. JAMA 214: 2163–2172.
54. Wang C. Zhai Z. Yang Y. Wu Q. Cheng Z. Liang L. (2010) Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 137: 254–262.
55. Wolde M. Söhne M. Quak E. MacGillavry M. Buller H. (2004) Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 164: 1685–1689.